CClinicalTrials.gg
RecruitingNCT06096948NEX-ENDOHSUpdated Oct 24, 2023

Nexpowder to Prevent Delayed Bleeding After Endoscopic Resection

An interventional study of NEXPOWDER-ENDOHS in Gastro Intestinal Bleeding and Polyps, sponsored by Erasme University Hospital. Recruiting at 12 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-10-24.

Sponsored by Erasme University Hospital · Not applicable, Interventional, and Prevention

From the registry’s dates

  • Primary completion was expected by Apr 2024, 2 years 5 months ago, but the record still lists the study as recruiting.
  • Started Oct 2023; still recruiting 2 years 11 months later.
Phase
Not applicable
Study type
Interventional
Enrollment
50
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Study summary

Safety and effectiveness of a new hemostatic system to prevent delayed bleeding after endoscopic resection in a selected high-risk population (NEXPOWDER- ENDOHS).

Indication:

Patients with indication of endoscopy resection by endoscopic mucal resection (EMR) or endoscopic submucosal dissection (ESD) with high risk of delayed bleeding (≥5%).

Hypotheses:

The use of NexpowderTM after upper and lower gastrointestinal ESD or EMR of ≥20mm in high-risk population will prevent and decrease delayed bleeding to less than 5%.

Read the detailed description

Hypotheses:

The use of NexpowderTM after upper and lower gastrointestinal ESD or EMR of ≥20mm in high-risk population will prevent and decrease delayed bleeding to less than 5%.

Study design:

This is an investigator-initiated, multicentric, international, open-label, non-controlled, prospective study:

  • All subjects with indications undergo screening and baseline visit,
  • Informed consent is obtained when scheduling the ESD or EMR procedure,
  • ESD or EMR is performed, at the end of resection, NexpowderTM is applied on the resected field,
  • A follow up visit is scheduled at 4 weeks.

Endpoints:

  • Primary:
  • Assess the delayed bleeding rate after ESD or EMR of ≥20mm in a selected high-risk population when using NexpowderTM at the end of the procedure.

This hypothesis is that the use of NexpowderTM will reduce the rate of DB from 16% (reported rate in the literature) to less than 5% (excepted observed rate during the study).

  • Secondary:
  • Safety of NexpowderTM endoscopic hemostasis system,
  • Procedure duration and NexpowderTM spaying duration,
  • Length of stay in hospital,
  • Post intervention pain,
  • Adverse events related to the use of NexpowderTM:
  • Per procedural
  • Early (up to controlled endoscopy or at 24hours post procedure)
  • Late (up to 4 weeks follow-up).
02

Conditions studied

  • Gastro Intestinal Bleeding
  • Polyps
03

In context

Gastrointestinal Hemorrhage

339 studies on the registry are indexed under Gastrointestinal Hemorrhage; 79 are open to participants now.

This study's planned enrollment of 50 is below the median of 87 across 211 interventional studies indexed under Gastrointestinal Hemorrhage.

Browse Gastrointestinal Hemorrhage studies →

Lead sponsor

Erasme University Hospital is the lead sponsor of 178 studies on the registry; 34 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • Age: ≥18 year of age at the time of informed consent,
  • Patients must have given written informed consent,
  • Subjects with documented lesions with indication of upper or lower endoscopic removal by ESD or EMR with high risk of delayed bleeding (+/-16%), namely:
  • All patients under anticoagulation (vitamin K antagonist, direct anticoagulant, non-fractionated heparin or low molecular weight heparin) or anti-aggregating (P2Y12 receptor antagonists),
  • Patients without anticoagulation or anti-aggregating with indication of duodenal EMR or ESD (if duodenal cold snare EMR: only under anticoagulant or P2Y12 receptor antagonist),
  • Resection field of ESD or EMR is ≥ 20mm (same size restriction in case of endoscopic papillectomy).

Exclusion criteria

Exclusion Criteria:

  • Resection bed \<20mm,
  • Subject currently enrolled in another interventional confounding research (no contra-indication for image or blood collection in another protocol),
  • Incapacitated subjects, pregnant or lactating women.
05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
50 participants (estimated)

Study arms

  • Experimental
    NEXPOWDER-ENDOHS

    Standard of care ESD or EMR procedure and application of Nexpowder on the resection site to prevent delayed bleeding.

    Device: NEXPOWDER-ENDOHS

Interventions

  • DeviceNEXPOWDER-ENDOHS

    Standard of care ESD or EMR procedure and application of Nexpowder on the resection site to prevent delayed bleeding.

06

What researchers measure

Primary outcomes

  1. Safety in terms of Adverse Events (AE related to Nexpowder)

    * number of intraprocedural complications (perforation,...) * number of post-procedure complications (delayed perforation, peritonitis,..)

    Time frame: 1 month

  2. Efficacy of Nexpowder in changing the delayed bleeding rate

    Decrease the delayed bleeding rate

    Time frame: 1 month

07

Study locations

9 of 12 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Oct 24, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06096948
Lead sponsor
Erasme University Hospital
Responsible party
Lemmers Arnaud (Professor Endoscopy Unit, Director of Clinic Department of Gastroenterology, Hepatopancreatology and Digestive Oncology Erasme Hospital,, Erasme University Hospital) — Principal investigator
First posted
Oct 24, 2023
Start date
Oct 15, 2023
Primary completion
Apr 30, 2024 (estimated)
Completion
Jul 30, 2024 (estimated)
Last update
Oct 24, 2023

Study contacts

Arnaud Lemmers
Contact
arnaud.lemmers@hubruxelles.be
+3225556559
Julia Chaves Rodriguez
Contact
julia.chaves.rodriguez@ulb.be
+3225551779

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion